



Kangen Pharmaceuticals, America LLC

From:	V.P., Clinical Operations
Date:	3 March 2021

Hi Dmytro and the entire GCT team,

Congratulations to all of you for screening the 100th subject (and #101 and #102) into the study for ROW!

Just yesterday we hit the 200th subject enrolled into the study and to hit these two milestones one day apart is quite an accomplishment! We would not be in this space had GCT not come aboard, identified excellent Investigators for the study and work closely with them to enroll subjects.

For the first time during the past 4+ years we are actually able now to see a light at the end of the study beginning to shine brighter every day that goes by!

You have my sincerest gratitude in what you have accomplished and will accomplish for this study. Well done! Now we just need to get to the final subjects enrolled and complete the study, with the hope that this will become the new standard-of-care for patients with this disease.

Best wishes,

V.P., Clinical Operations
Kangen Pharmaceuticals